PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

NCT03365791 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer
Gastric Adenocarcinoma
Esophageal Adenocarcinoma
Castration Resistant Prostate Adenocarcinoma
Soft Tissue Sarcoma
Ovarian Adenocarcinoma
Advanced Well-differentiated Neuroendocrine Tumors
Diffuse Large B Cell Lymphoma

Interventions

BIOLOGICAL: PDR001
BIOLOGICAL: LAG525

Sponsor

Novartis Pharmaceuticals